Loading...
Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality
AIM: Patients with colorectal liver metastases (CRLM) benefit from liver resection. Bevacizumab is commonly used in these patients resulting in a greater number of patients receiving an operation for a potentially curative liver resection, with initially unresectable liver metastases. Our purpose wa...
Na minha lista:
| Udgivet i: | Hepat Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Future Medicine Ltd
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095412/ https://ncbi.nlm.nih.gov/pubmed/30190972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.17 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|